Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in phase II clinical trial for the treatment of non-small cell lung cancer. The company is also developing Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12 that is in phase I/II clinical trial to treat advanced solid tumors; Dekavil (F8IL10), an anti-inflammatory product, which is in phase II clinical trial for the treatment of chronic inflammatory disorders; Onco IX (PHC-102), a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressed on the surface of solid tumors that is in phase 1 clinical trial; and OncoFAP, a small molecule radiotracer for the non-invasive detection of various metastatic solid tumors targeting fibroblast activation protein, which is in phase 1 clinical trial. In addition, it is developing Tripokin, a fully-human immunostimulatory product consisting of tumor necrosis factor and interleukin-2 fused into one molecular entity, which is in preclinical stage. Philogen S.p.A. was founded in 1996 and is based in Siena, Italy.
तुलना करने के लिए मीट्रिक्स | PHIL | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधPHILपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −25.6x | −2.9x | −0.6x | |
PEG अनुपात | 0.00 | −0.06 | 0.00 | |
क़ीमत/बुक | 9.9x | 1.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 191.7x | 11.2x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | 28.7% | 258.9% | 54.8% | |
उचित मूल्य अपसाइड | अनलॉक करें | 5.3% | 7.9% | अनलॉक करें |